Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8358) 8358
Newsletter (432) 432
Newspaper Article (64) 64
Magazine Article (63) 63
Book Chapter (44) 44
Dissertation (29) 29
Publication (27) 27
Conference Proceeding (7) 7
Government Document (4) 4
Web Resource (4) 4
Journal / eJournal (3) 3
Paper (3) 3
Book Review (2) 2
Book / eBook (1) 1
Streaming Video (1) 1
Trade Publication Article (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
azithromycin (5629) 5629
science & technology (5074) 5074
humans (4866) 4866
life sciences & biomedicine (4833) 4833
azithromycin - therapeutic use (2629) 2629
male (2598) 2598
female (2588) 2588
anti-bacterial agents - therapeutic use (2259) 2259
infectious diseases (1803) 1803
biological and medical sciences (1767) 1767
medical sciences (1712) 1712
adult (1616) 1616
pharmacology & pharmacy (1373) 1373
microbiology (1359) 1359
azithromycin - pharmacology (1308) 1308
azithromycin - administration & dosage (1252) 1252
antibiotics (1247) 1247
pharmacology. drug treatments (1237) 1237
anti-bacterial agents - pharmacology (1208) 1208
middle aged (1150) 1150
antibiotics. antiinfectious agents. antiparasitic agents (1048) 1048
anti-bacterial agents - administration & dosage (995) 995
antibacterial agents (953) 953
treatment outcome (928) 928
research (878) 878
animals (869) 869
adolescent (849) 849
microbial sensitivity tests (844) 844
child (783) 783
aged (719) 719
drug therapy (706) 706
health aspects (669) 669
abridged index medicus (662) 662
azithromycin - adverse effects (631) 631
immunology (631) 631
infections (621) 621
child, preschool (599) 599
general & internal medicine (579) 579
care and treatment (552) 552
analysis (538) 538
anti-bacterial agents - adverse effects (524) 524
drug resistance (521) 521
medicine, general & internal (513) 513
dosage and administration (473) 473
infant (467) 467
drug therapy, combination (448) 448
risk factors (434) 434
drug resistance, bacterial (426) 426
young adult (417) 417
erythromycin (414) 414
pediatrics (404) 404
clarithromycin (396) 396
bacteria (392) 392
administration, oral (380) 380
bacterial diseases (380) 380
research article (375) 375
children (361) 361
azithromycin - pharmacokinetics (359) 359
clinical trials (354) 354
macrolides (354) 354
medical research (350) 350
pneumonia (337) 337
patients (336) 336
erythromycin - pharmacology (330) 330
antimicrobial agents (329) 329
drug administration schedule (325) 325
chlamydia infections - drug therapy (319) 319
medicine (318) 318
covid-19 (316) 316
chlamydia trachomatis (314) 314
human bacterial diseases (314) 314
mice (309) 309
ciprofloxacin (307) 307
time factors (300) 300
respiratory system (295) 295
anti-bacterial agents - pharmacokinetics (288) 288
retrospective studies (282) 282
usage (277) 277
erythromycin - analogs & derivatives (276) 276
drug resistance in microorganisms (273) 273
inflammation (271) 271
antimicrobial resistance (268) 268
double-blind method (267) 267
medicine, experimental (264) 264
bacterial infections and mycoses (262) 262
drugs (261) 261
pregnancy (258) 258
doxycycline (254) 254
ceftriaxone (250) 250
hydroxychloroquine (247) 247
trachoma (245) 245
dose-response relationship, drug (244) 244
prospective studies (244) 244
erythromycin - therapeutic use (242) 242
cystic fibrosis (240) 240
clarithromycin - pharmacology (239) 239
ophthalmology (239) 239
mortality (236) 236
public health (234) 234
follow-up studies (233) 233
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8491) 8491
Japanese (131) 131
French (122) 122
Spanish (99) 99
Russian (85) 85
German (80) 80
Chinese (74) 74
Portuguese (64) 64
Italian (31) 31
Croatian (23) 23
Polish (22) 22
Korean (18) 18
Turkish (16) 16
Persian (9) 9
Bulgarian (8) 8
Czech (6) 6
Danish (6) 6
Dutch (6) 6
Norwegian (6) 6
Romanian (4) 4
Hungarian (3) 3
Finnish (2) 2
Hebrew (2) 2
Slovak (2) 2
Swedish (2) 2
Ukrainian (2) 2
Arabic (1) 1
Bosnian (1) 1
Serbian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Synthesis and antibacterial activity of novel 4″-O-(1-aralkyl-1,2,3-triazol-4-methyl-carbamoyl) azithromycin analogs
by Wang, Yinhu and Cong, Chao and Chai, Wern Chern and Dong, Ruiqian and Jia, Li and Song, Di and Zhou, Ziteng and Ma, Shutao
Bioorganic & medicinal chemistry letters, ISSN 0960-894X, 08/2017, Volume 27, Issue 16, pp. 3872 - 3877
Antibacterial activity | Erythromycin-resistant bacteria | Synthesis | Bacterial resistance | 1,2,3-Triazol azithromycin analogs | Streptococcus pneumoniae - drug effects | Azithromycin - chemistry | Streptococcus pyogenes - drug effects | Escherichia coli - drug effects | Structure-Activity Relationship | Azithromycin - analogs & derivatives | Azithromycin - pharmacology | Anti-Bacterial Agents - chemical synthesis | Dose-Response Relationship, Drug | Microbial Sensitivity Tests | Anti-Bacterial Agents - chemistry | Azithromycin - chemical synthesis | Anti-Bacterial Agents - pharmacology | Molecular Structure | Staphylococcus aureus - drug effects | Drug resistance in microorganisms | Pneumonia | Bacterial pneumonia | Azithromycin | Bacteria | Antibacterial agents | Child care | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial
by Wong, Conroy, Dr and Jayaram, Lata, FRACP and Karalus, Noel, FRACP and Eaton, Tam, FRACP and Tong, Cecilia, RN and Hockey, Hans, MSc and Milne, David, FRANZCR and Fergusson, Wendy, BHSc and Tuffery, Christine, BN and Sexton, Paul, FRACP and Storey, Louanne, BSc and Ashton, Toni, Prof
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 380, Issue 9842, pp. 660 - 667
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Errors of metabolism | Public health. Hygiene-occupational medicine | Public health. Hygiene | General aspects | Prevention and actions | Biological and medical sciences | Metabolic diseases | Medical sciences | Miscellaneous hereditary metabolic disorders | Double-Blind Method | Drug Administration Schedule | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Male | Treatment Outcome | Secondary Prevention | Azithromycin - administration & dosage | Cystic Fibrosis - complications | Vital Capacity - drug effects | Anti-Bacterial Agents - therapeutic use | Azithromycin - adverse effects | Azithromycin - therapeutic use | Bronchiectasis - prevention & control | Quality of Life | Adult | Female | Aged | Anti-Bacterial Agents - adverse effects | Anti-Bacterial Agents - administration & dosage | Bronchiectasis - physiopathology | Bronchiectasis - etiology | Prevention | Usage | Bronchiectasis | Research | Azithromycin | Medical research | Antibiotics | Drug therapy | Mortality | Streptococcus infections | Quality of life | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Effect of Azithromycin Maintenance Treatment on Infectious Exacerbations Among Patients With Non–Cystic Fibrosis Bronchiectasis: The BAT Randomized Controlled Trial
by Altenburg, Josje and de Graaff, Casper S and Stienstra, Ymkje and Sloos, Jacobus H and van Haren, Eric H. J and Koppers, Ralph J. H and van der Werf, Tjip S and Boersma, Wim G
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 03/2013, Volume 309, Issue 12, pp. 1251 - 1259
LOW-DOSE AZITHROMYCIN | LONG-TERM AZITHROMYCIN | PSEUDOMONAS-AERUGINOSA | DOUBLE-BLIND | GEORGES RESPIRATORY QUESTIONNAIRE | STAPHYLOCOCCUS-AUREUS | PULMONARY-FUNCTION | PLACEBO-CONTROLLED TRIAL | MACROLIDE RESISTANCE | HEALTH-STATUS | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Errors of metabolism | General aspects | Respiratory system : syndromes and miscellaneous diseases | Biological and medical sciences | Metabolic diseases | Medical sciences | Miscellaneous hereditary metabolic disorders | Pneumology | Sputum - microbiology | Double-Blind Method | Bacterial Infections - etiology | Humans | Middle Aged | Respiratory Tract Infections - prevention & control | Drug Resistance, Bacterial | Male | Inflammation | Lung - physiopathology | Biomarkers - blood | Anti-Bacterial Agents - therapeutic use | Azithromycin - adverse effects | Bacterial Infections - prevention & control | Bronchiectasis - complications | Azithromycin - therapeutic use | Quality of Life | Adult | Female | Respiratory Tract Infections - etiology | Aged | Anti-Bacterial Agents - adverse effects | Respiratory Function Tests | Clinical trials | Cystic fibrosis | Antibiotics | Medical treatment | Clinical outcomes | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text The Story of Azithromycin
by Banić Tomišić, Z
Kemija u industriji; časopis kemičara i tehnologa Jugoslavije, ISSN 0022-9830, 12/2011, Volume 60, Issue 12, pp. 603 - 617
Azithromycin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
by Million, Matthieu and Lagier, Jean-Christophe and Gautret, Philippe and Colson, Philippe and Fournier, Pierre-Edouard and Amrane, Sophie and Hocquart, Marie and Mailhe, Morgane and Esteves-Vieira, Vera and Doudier, Barbara and Aubry, Camille and Correard, Florian and Giraud-Gatineau, Audrey and Roussel, Yanis and Berenger, Cyril and Cassir, Nadim and Seng, Piseth and Zandotti, Christine and Dhiver, Catherine and Ravaux, Isabelle and Tomei, Christelle and Eldin, Carole and Tissot-Dupont, Hervé and Honoré, Stéphane and Stein, Andreas and Jacquier, Alexis and Deharo, Jean-Claude and Chabrière, Eric and Levasseur, Anthony and Fenollar, Florence and Rolain, Jean-Marc and Obadia, Yolande and Brouqui, Philippe and Drancourt, Michel and La Scola, Bernard and Parola, Philippe and Raoult, Didier
Travel medicine and infectious disease, ISSN 1477-8939, 05/2020, Volume 35, pp. 101738 - 101738
COVID-19 | SARS-CoV-2 | Hydroxychloroquine | Azithromycin | Public, Environmental & Occupational Health | Infectious Diseases | Life Sciences & Biomedicine | Science & Technology | Hydroxychloroquine - therapeutic use | Pandemics | Follow-Up Studies | Coronavirus Infections - drug therapy | Humans | Middle Aged | Pneumonia, Viral - drug therapy | Male | Azithromycin - administration & dosage | Hydroxychloroquine - adverse effects | Coronavirus Infections - mortality | Viral Load | Young Adult | Time Factors | Polymerase Chain Reaction | Aged, 80 and over | Adult | Female | Retrospective Studies | Drug Therapy, Combination | France | Antiviral Agents - therapeutic use | Treatment Outcome | Antiviral Agents - administration & dosage | Hydroxychloroquine - administration & dosage | Azithromycin - adverse effects | Azithromycin - therapeutic use | Coronavirus Infections - virology | Antiviral Agents - adverse effects | Adolescent | Aged | Pneumonia, Viral - mortality | Betacoronavirus - genetics | Pneumonia, Viral - virology | Pneumonia | Toxicity | Infections | Receptors | Electrocardiography | Serum | Drug dosages | Failure | Ventilators | Oxygen therapy | Nucleotide sequence | Complications | Coronaviruses | Patients | Polymerase chain reaction | Severe acute respiratory syndrome coronavirus 2 | Persistence | Infectious diseases | Hospitals | DNA | Fatalities | Electrolytes | Skin | Symptoms | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
by Rosenberg, Eli S and Dufort, Elizabeth M and Udo, Tomoko and Wilberschied, Larissa A and Kumar, Jessica and Tesoriero, James and Weinberg, Patti and Kirkwood, James and Muse, Alison and DeHovitz, Jack and Blog, Debra S and Hutton, Brad and Holtgrave, David R and Zucker, Howard A
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 05/2020, Volume 323, Issue 24, pp. 2493 - 2502
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hydroxychloroquine - therapeutic use | Arrhythmias, Cardiac - chemically induced | Pandemics | Coronavirus Infections - drug therapy | Humans | Middle Aged | Pneumonia, Viral - drug therapy | Male | Hydroxychloroquine - adverse effects | Coronavirus Infections - mortality | COVID-19 | Young Adult | SARS-CoV-2 | Betacoronavirus | Adult | Female | Retrospective Studies | Drug Therapy, Combination | New York | Anti-Infective Agents - adverse effects | Hospital Mortality | Proportional Hazards Models | Anti-Infective Agents - therapeutic use | Logistic Models | Hospitalization | Azithromycin - adverse effects | Azithromycin - therapeutic use | Adolescent | Heart Arrest - etiology | Aged | Pneumonia, Viral - mortality | Hospital patients | Care and treatment | Hydroxychloroquine | Medical examination | Patient outcomes | Azithromycin | Drug therapy, Combination | Drug therapy | Health aspects | Testing | Heart | Arrhythmia | Health services | Viral diseases | Medical records | Metropolitan areas | Regression models | Electrocardiography | EKG | Statistical analysis | Mortality | Diabetes mellitus | Pharmacology | Regression analysis | Coronaviruses | Chemical compounds | Patients | Respiratory rate | Statistical models | Models | Aspartate aminotransferase | Respiration | Prolongation | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial
by Brusselle, Guy G and VanderStichele, Christine and Jordens, Paul and Deman, René and Slabbynck, Hans and Ringoet, Veerle and Verleden, Geert and Demedts, Ingel K and Verhamme, Katia and Delporte, Anja and Demeyere, Bénédicte and Claeys, Geert and Boelens, Jerina and Padalko, Elizaveta and Verschakelen, Johny and Van Maele, Georges and Deschepper, Ellen and Joos, Guy F P
Thorax, ISSN 0040-6376, 04/2013, Volume 68, Issue 4, pp. 322 - 329
Life Sciences & Biomedicine | Respiratory System | Science & Technology | Double-Blind Method | Humans | Middle Aged | Male | Treatment Outcome | Azithromycin - administration & dosage | Asthma - drug therapy | Disease Progression | Anti-Bacterial Agents - therapeutic use | Azithromycin - therapeutic use | Adult | Female | Drug Therapy, Combination | Anti-Bacterial Agents - administration & dosage | Prevention | Respiratory tract infections | Care and treatment | Azithromycin | Dosage and administration | Research | Asthma | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review
by O'Brien, Kieran S and Emerson, Paul and Hooper, PJ and Reingold, Arthur L and Dennis, Elena G and Keenan, Jeremy D and Lietman, Thomas M and Oldenburg, Catherine E
The Lancet infectious diseases, ISSN 1473-3099, 01/2019, Volume 19, Issue 1, pp. e14 - e25
Life Sciences & Biomedicine | Infectious Diseases | Science & Technology | Pneumococcal Infections - drug therapy | Prevalence | Humans | Child, Preschool | Infant | Male | Azithromycin - administration & dosage | Anti-Bacterial Agents - therapeutic use | Trachoma - epidemiology | Female | Pneumococcal Infections - microbiology | Anti-Bacterial Agents - adverse effects | Drug Resistance, Bacterial - drug effects | Chlamydia trachomatis - drug effects | Child | Streptococcus pneumoniae - drug effects | Administration, Oral | Trachoma - drug therapy | Treatment Outcome | Azithromycin - adverse effects | Macrolides - adverse effects | Azithromycin - therapeutic use | Adolescent | Macrolides - therapeutic use | Anti-Bacterial Agents - administration & dosage | Trachoma - microbiology | Mortality | Bias | Azithromycin | Trachoma | Antimicrobial agents | Systematic review | Chlamydia trachomatis | Organisms | Grey literature | Drug resistance | Antiinfectives and antibacterials | Streptococcus infections | Studies | Sexually transmitted diseases | Reviews | E coli | Children | Antimicrobial resistance | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Combination of Clindamycin and Azithromycin as Alternative Treatment for Toxoplasma gondii Encephalitis
by Shiojiri, Daisuke and Kinai, Ei and Teruya, Katsuji and Kikuchi, Yoshimi and Oka, Shinichi
Emerging infectious diseases, ISSN 1080-6040, 04/2019, Volume 25, Issue 4, pp. 841 - 843
alternative treatment | Toxoplasma gondii | HIV | Japan | parasites | azithromycin | clindamycin | meningitis/encephalitis | Toxoplasmic encephalitis | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Science & Technology | Toxoplasmosis, Cerebral - diagnosis | Toxoplasmosis, Cerebral - parasitology | Humans | Middle Aged | Male | Treatment Outcome | Azithromycin - administration & dosage | Toxoplasmosis, Cerebral - drug therapy | Clindamycin - therapeutic use | Magnetic Resonance Imaging | Azithromycin - therapeutic use | Clindamycin - administration & dosage | Antiprotozoal Agents - administration & dosage | Biomarkers | Toxoplasma - drug effects | Antiprotozoal Agents - therapeutic use | Drug Therapy, Combination | Encephalitis | Sulfadiazine | Care and treatment | Clindamycin | World health | Azithromycin | Pyrimethamine | Drug therapy, Combination | meningitis | Combination of Clindamycin and Azithromycin as Alternative Treatment for | Research Letter
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Azithromycin and the Risk of Cardiovascular Death
by Ray, Wayne A and Murray, Katherine T and Hall, Kathi and Arbogast, Patrick G and Stein, C. Michael
The New England journal of medicine, ISSN 0028-4793, 05/2012, Volume 366, Issue 20, pp. 1881 - 1890
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | General aspects | Medical sciences | Antibacterial agents | Pharmacology. Drug treatments | Antibiotics. Antiinfectious agents. Antiparasitic agents | Arrhythmias, Cardiac - chemically induced | United States | Humans | Middle Aged | Male | Risk | Death, Sudden, Cardiac - etiology | Incidence | Anti-Bacterial Agents - therapeutic use | Azithromycin - adverse effects | Azithromycin - therapeutic use | Cardiovascular Diseases - mortality | Adult | Female | Anti-Bacterial Agents - adverse effects | Cardiovascular Diseases - chemically induced | Retrospective Studies | Medicaid | Cohort Studies | Dose-response relationship (Biochemistry) | Causes of | Complications and side effects | Cardiovascular diseases | Azithromycin | Levofloxacin | Hospitals | Antibiotics | Amoxicillin | Macrolide antibiotics | Death | Ciprofloxacin | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Biomimetic electrochemical sensor for the highly selective detection of azithromycin in biological samples
by Stoian, Ioan-Adrian and Iacob, Bogdan-Cezar and Dudaș, Cosmina-Larisa and Barbu-Tudoran, Lucian and Bogdan, Diana and Marian, Iuliu Ovidiu and Bodoki, Ede and Oprean, Radu
Biosensors & bioelectronics, ISSN 0956-5663, 05/2020, Volume 155, pp. 112098 - 112098
Urine | Plasma | Molecularly imprinted polymers | Electrochemical sensor | Tears | Azithromycin | Physical Sciences | Chemistry | Nanoscience & Nanotechnology | Life Sciences & Biomedicine | Electrochemistry | Science & Technology - Other Topics | Biophysics | Chemistry, Analytical | Biotechnology & App